

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 27/00, 29/00, 31/00, 33/00	A1	(11) International Publication Number: WO 99/01167 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/US97/20055 (22) International Filing Date: 31 October 1997 (31.10.97) (30) Priority Data: 08/886,720 1 July 1997 (01.07.97) US (71) Applicant: MINNESOTA MINING AND MANUFACTURING COMPANY (US); 3M Center, P.O. Box 33427, Saint Paul, MN 55133-3427 (US). (72) Inventors: WIRT, David, F.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). SIRVIO, Larry, M.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). (74) Agents: ROGERS, James, A. et al.; Minnesota Mining and Manufacturing Company, Office of Intellectual Property Counsel, P.O. Box 33427, Saint Paul, MN 55133-3427 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS FOR MODIFYING SURFACES USING THE REACTION PRODUCT OF A WATER-INSOLUBLE POLYMER AND A POLYALKYLENE IMINE (57) Abstract A process for modifying a surface of an article that includes treating a surface with a solution that includes an organic solvent, and the reaction product of a substantially water insoluble polymer and a polyalkylene imine to form a modified surface. Additionally, a biologically active agent such as an anti-thrombotic agent may be attached to the modified surface.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROCESS FOR MODIFYING SURFACES USING THE
REACTION PRODUCT OF A WATER-INSOLUBLE
POLYMER AND A POLYALKYLENE IMINE

5

The invention relates to modifying the surface of an article.

Surfaces of, e.g., medical devices must often be modified. For example, the
10 surfaces of medical devices that are in direct contact with blood or blood products
(e.g., blood oxygenators, blood pumps, catheters, and tubing) have been treated
with biologically active agents such as heparin or derivatives thereof to make such
surfaces nonthrombogenic in an effort to prevent clotting or clot formation related
to surface contact with blood or blood products.

15

In one aspect, the invention features a process for modifying the surface of
an article that includes treating the surface with a solution that includes (a) an
organic solvent, and (b) the reaction product of a substantially water insoluble
polymer and a polyalkylene imine (e.g., polyethylene imine) to form a modified
20 surface.

In one preferred embodiment, the treated surface may be reacted further
with a biologically active agent. The biologically active agent may include
negatively charged materials. Specific examples of biologically active agents
include anti-thrombotic agents (e.g., a glycosaminoglycan (or a derivative thereof)
25 such as heparin or a heparin derivative). Other examples of suitable biologically
active agents include heparin sulfate, hyaluronic acid, dermatan sulfate, chitosan,
derivatives thereof, and combinations thereof.

Preferred substantially water-insoluble polymers include functional groups
such as ester groups that are capable of forming a covalent bond with the
30 polyalkylene imine. Specific examples include the reaction product of an alkyl
acrylate and an alkyl methacrylate (e.g., isooctyl acrylate and methyl methacrylate);
the reaction product of an alkyl methacrylate, an alkylacrylate, and N-vinyl
pyrrolidone (e.g., methyl methacrylate, isooctyl acrylate, and N-vinyl pyrrolidone);
and the reaction product of an alkyl acrylate, an alkyl methacrylate, and a
35 hydroxyalkyl methacrylate (e.g., isooctyl acrylate, methyl methacrylate, and
hydroxypropyl methacrylate). The acrylate, methacrylate, and N-vinyl pyrrolidone

may be provided in the form of monomers, oligomers, or a combination thereof.

The invention also features an article that includes a substrate having a modified surface that includes the reaction product of a substantially water insoluble polymer and a polyalkylene imine. The article may further include a biologically
5 active agent bound to the surface.

Throughout this application the following definitions apply:

A "biologically active agent" is a material which, when in contact with a patient's blood, plasma, or other body fluids or tissues under physiological conditions, exhibits biological activity. For instance, a material such as heparin is
10 "biologically active" in the sense that it acts as an anti-coagulant in the presence of blood.

The invention provides a simple and effective means for modifying the surface of an article, e.g., such that when in contact with a patient's blood, plasma, or other body fluids, the surface does not cause an adverse physiological reaction.
15

The present invention provides a process for producing modified surfaces (e.g., the surfaces of medical devices such as filters, membranes, tubes, catheters, oxygenator, intravascular probes, blood pumps, blood gas sensing devices, and the like). The surface may be a polymer, ceramic, or metal surface. Examples of
20 suitable polymer surfaces include polypropylene, poly (vinyl chloride), poly (methyl methacrylate), polytetrafluoroethylene, polysulfone, silicone rubber, poly (ethylene terephthalate), polycarbonate, polyethylene, polystyrene, and polyurethane.

In general, the surface is contacted with a priming solution that contains an organic solvent and the reaction product of a polyalkylene imine, such as
25 polyethylene imine, and a substantially water insoluble polymer, and then dried. The resulting primed surface is capable of binding with a biologically active agent. Although the system is designed to be functional after a single coating step, the solution may be coated on the surface and dried as many times as is necessary to achieve the desired concentration of functional groups on the surface. The
30 particular amount of coating and concentration of functional groups on the surface will depend upon the particular application for which the treated surface is intended.

The surface may then be contacted with a biologically active agent to bind the biologically active agent to the primed surface. The biologically active agent
35 may be an anti-thrombotic agent (e.g., a glycosaminoglycan (or derivative thereof)

such as heparin or a heparin derivative), an anti-microbial agent, a therapeutic agent (e.g., a drug or growth factor), an enzyme, or a cell attachment protein. Other examples of suitable biologically active agents include heparin, heparan sulfate, hyaluronic acid, dermatan sulfate, chitosan, and derivatives thereof. The agents
5 may be used alone or in combination with each other.

Binding may be either ionic or covalent, with covalent being preferred. In the case of ionic binding, it is preferred that the biologically active agent include one or more negatively charged groups. Following addition of the biologically active agent, the biologically active agent may then be treated with a crosslinking agent, if
10 desired.

In the case of covalent binding, it is preferred to contact the primed surface with a biologically active agent having free aldehyde groups (generated, e.g., by periodate oxidation) in the presence of a reducing agent such as sodium cyanoborohydride. The covalent binding most likely occurs via formation of a
15 Schiff's base initially, which is then readily reduced to a secondary amine in the presence of the sodium cyanoborohydride.

Covalent binding may also be accomplished using a coupling agent such as a carbodiimide, rather than sodium cyanoborohydride. In this case, the covalent linkage occurs between carboxylate groups on the biologically active agent and
20 amine groups on the primed surface.

Preferred priming solutions include between about 0.1 to about 20% solids in a solution that includes between about 50 and about 99.9% organic solvent and up to about 50% water. The weight to weight ratio of substantially water insoluble polymer to polyethylene imine is preferably between about 0.1:1 and about 10:1,
25 more preferably about 4:1.

Suitable polyalkylene imines are those having an average molecular weight of between about 300 and 1,000,000. One example of a suitable polyalkylene imine is polyethylene imine having an average molecular weight of 750,000, available from the Aldrich Chemical Co., Milwaukee, Wisconsin.

30 Preferred substantially water insoluble polymers are those polymers that provide functional groups capable of forming a covalent bond with the amine groups of the polyalkylene imine while not interfering with the ability of the polyalkylene imine to bind to a biologically active agent. The polymer preferably is soluble in those organic solvents in which the polyalkylene imine is soluble.

Suitable substantially water insoluble polymers include substantially water insoluble acrylate polymers such as, e.g., alkyl acrylate-alkyl methacrylate copolymers (e.g., copolymers of isooctyl acrylate and methyl methacrylate), alkyl methacrylate-alkyl acrylate-N-vinyl pyrrolidone terpolymers (e.g., methyl
5 methacrylate-isooctyl acrylate-N-vinyl pyrrolidone), and alkyl acrylate-alkyl methacrylate-hydroxyalkyl methacrylate terpolymers (e.g., isooctyl acrylate-methyl methacrylate-hydroxypropyl methacrylate).

Examples of alkyl methacrylate-alkyl acrylate-N-vinyl pyrrolidone terpolymers, and their methods of manufacture, are described in U.S. Patent No.
10 4,584,192 (Dell), incorporated herein by reference.

Preferred organic solvents are those capable of dissolving both the substantially water insoluble polymer and polyalkylene imine, and rapidly evaporating after the application of the priming solution to the substrate surface. Suitable organic solvents include tetrahydrofuran and alkyl alcohols such as, e.g.,
15 methanol, ethanol, and isopropyl alcohol.

The invention will now be further described by way of the following non-limiting examples.

20 Example 1

Methyl methacrylate monomers, isooctyl acrylate monomers and N-vinyl pyrrolidone monomers were polymerized as described in Examples 2-8, formulation D of U.S. Patent No. 4,584,192, to form a terpolymer. The terpolymer was then repeatedly washed and distilled so as to remove the acetone. Once the acetone was
25 removed, the terpolymer was placed in isopropyl alcohol.

The terpolymer solution and polyethylene imine were then placed in a solution of isopropyl alcohol and water. The resulting solution contained 4:1 polyethylene imine/terpolymer, 2.5% solids solution in 82.5% isopropyl alcohol and 15% water. The solution was allowed to react for four hours at 50EC, after which
30 it was coated on a piece of woven polyester. After evaporation of the solvent, a portion of the sample was separated and rinsed with water. It was then stained with 8-hydroxy-7-(4-sulfo-1-naphthylazo)-5-quinoline sulfonic acid (SNAZOXS), which revealed the presence of PEI.

The remaining portion of the sample was rinsed with 25% saline solution
35 and then stained with SNAZOXS. Staining also revealed the presence of PEI,

demonstrating that the PEI does not rinse off even with saline solution.

Example 2

Two grams (g) of a isooctyl acrylate/methyl methacrylate (IOA/MMA) copolymer, having 55 parts IOA and 45 parts MMA, was dissolved in 35g of tetrahydrofuran (THF). Two grams of polyethylene imine (PEI) (average molecular weight of 750,000, available from Aldrich Chemical Co., Milwaukee, Wisconsin) was added to the IOA/MMA THF solution and the mixture was allowed to react for four hours at 50EC. The solution was coated on a piece of woven polyester. After evaporation of the solvent, the polyester sample was rinsed with a 25% saline solution. The polyester sample was then stained with 8-hydroxy-7-(4-sulfo-1-naphthylazo)-5-quinoline sulfonic acid (SNAZOXS), which revealed the presence of PEI.

Example 3

Two grams of IOA/MMA/hydroxypropyl methacrylate (HPMA) terpolymer, having 50 parts IOA, 40 parts MMA and 10 parts HPMA, was dissolved in 35g of THF. Two grams of PEI was added to the IOA/MMA/HPMA THF solution and the mixture was allowed to react for four hours at 50EC. The solution was coated on a piece of woven polyester. After evaporation of the solvent, the polyester sample was rinsed with a 25% saline solution. The polyester sample was then stained with SNAZOXS, which revealed the presence of PEI.

Example 4

An isooctyl acrylate-methyl methacrylate-N-vinyl pyrrolidone terpolymer was prepared following the procedure of Example 1 except that a polycarbonate sample was dip coated in the solution and allowed to dry. Next, the dried sample was rinsed thoroughly with water, after which heparin was attached to the primed polycarbonate surface by immersing the sample in a citrate-buffered saline solution containing 0.04% periodate oxidized heparin and 0.004% sodium cyanoborohydride (pH = 3.9) for a period of 30 minutes at 50EC. The heparinized sample was then rinsed for five minutes in 25% saline solution to remove ionically bound heparin, leaving only covalently bound heparin. The sample was subjected to a thrombin inhibition assay following the procedure described in Sirvio et al., U.S. Patent No. 5,532,311 (hereby incorporated by reference). The results of the assay

demonstrated that the activity of heparin on the sample surface corresponded to 0.14 micrograms/cm².

What is claimed is:

1. A process for modifying a surface of an article comprising:
treating a surface with a solution comprising
 - (a) an organic solvent, and
 - 5 (b) the reaction product of a substantially water insoluble polymer and a polyalkylene imine to form a modified surface.
2. The process of claim 1, further comprising contacting said modified
surface with a biologically active agent to bind said biologically active agent to said
10 surface.
3. The process of claim 2, wherein said biologically active agent
comprises a negatively charged material.
- 15 4. The process of claim 2, wherein said biologically active agent
comprises an anti-thrombotic agent.
5. The process of claim 2, wherein said biologically active agent
comprises a glycosaminoglycan or a derivative thereof.
20
6. The process of claim 2, wherein said biologically active agent
comprises heparin or a derivative thereof.
7. An article comprising a substrate having a surface that has been
25 modified using the process of claim 1.
8. The article of claim 7, wherein said polyalkylene imine comprises
polyethylene imine.
- 30 9. The article of claim 7, further comprising a biologically active agent
bound to said surface.
10. The article of claim 9, wherein said biologically active agent
comprises a negatively charged material.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/20055

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L27/00 A61L29/00 A61L31/00 A61L33/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EP 0 693 293 A (TERUMO CORP) 24 January 1996 see page 6, line 39 - page 7, line 3 see page 8, line 39 - line 56 see example 11 ---	1-10
E	WO 97 46590 A (GORE ENTERPRISE HOLDINGS INC) 11 December 1997 see abstract see page 17, line 24 - line 32 see claims 1,10,57,61 ---	1.2,7-9
A	EP 0 351 314 A (TERUMO CORP) 17 January 1990 see abstract see page 3, line 43 - line 57 see page 9, line 32 - line 46 -----	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 February 1998

Date of mailing of the international search report

03/03/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heck, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/20055

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0693293 A	24-01-96	JP 8019598 A	23-01-96
		JP 8019599 A	23-01-96
		JP 8024327 A	30-01-96
		JP 8024328 A	30-01-96
		JP 8033704 A	06-02-96
		CA 2153466 A	08-01-96
		US 5670558 A	23-09-97

WO 9746590 A	11-12-97	NONE	

EP 0351314 A	17-01-90	JP 2021875 A	24-01-90
		JP 2046856 A	16-02-90
		DE 68920925 D	16-03-95
		DE 68920925 T	22-06-95
		JP 2119867 A	07-05-90
		JP 6038851 B	25-05-94

